TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
AVBP

ArriVent BioPharma, Inc.

Healthcare · Biotechnology

30.30$ -0.1% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Income Statement AVBP
Line item 2021 2022 2023 2024 2025
– – – – –
– +373.0% +113.2% +21.8% +94.1%
– +114.6% +49.9% +57.7% +58.0%
– +324.4% +102.1% +26.4% +88.2%
– – – – –
– – – – –
– – – – –
– – – – –
– – – – –

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?